Tumor lysis syndrome signal with the combination of encorafenib and binimetinib for malignant melanoma: a pharmacovigilance study using data from the FAERS database
Stronger disproportionate signal of TLS was detected in MM patients using the combination of encorafenib and binimetinib than other drugs. Further research is needed to investigate the underlying mechanisms and identify patient-related predisposing factors to support safe prescribing of the combination of encorafenib and binimetinib.
Authors
- Yoshihiro Noguchi (ORCID: https://orcid.org/0000-0002-9110-9604)
- Mayur Sarangdhar (ORCID: https://orcid.org/0000-0001-9247-8375)
- Miao Yan (ORCID: https://orcid.org/0000-0002-3582-8305)
- Shuang Xia (ORCID: https://orcid.org/0000-0002-1059-1794)
- Jingwen Xu (ORCID: https://orcid.org/0009-0000-7306-3529)
- Kang-Xin Yan
Institutions
- Cincinnati Children's Hospital Medical Center (US)
- Hunan International Economics University (CN)
- Central South University (CN)
- Gifu Pharmaceutical University (JP)
- Xuzhou Medical College (CN)
- Second Xiangya Hospital of Central South University (CN)
- University of Cincinnati Medical Center (US)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-09-09
- DOI
- https://doi.org/10.3389/fphar.2024.1413154
- Citations
- 1
- Primary Topic
- Methemoglobinemia and Tumor Lysis Syndrome
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- Central South University
- Division of Graduate Education